University Hospital of Leipzig
Welcome,         Profile    Billing    Logout  
 8 Trials 
44 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Franke, Georg-Nikolaus
IDUNN, NCT04629833 / 2019-001462-15: Treatment of Steroid-Refractory Acute Graft-versus-host Disease with Mesenchymal Stromal Cells Versus Best Available Therapy

Recruiting
3
210
Europe
MC0518, BAT
medac GmbH
Steroid-refractory Acute Graft-versus-host Disease
08/27
08/30
OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting
3
225
Europe, Canada, Japan, US, RoW
Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)
F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi
Invasive Aspergillosis
09/25
11/26
MO-TRANS, NCT05429632 / 2021-002864-36: Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Active, not recruiting
3
249
Europe, Japan, US, RoW
mocravimod
Priothera SAS, Priothera S.A.S.
Adult Acute Myeloid Leukemia
11/25
11/25
AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Recruiting
3
482
Europe
Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD)
Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH
Multiple Myeloma
03/28
03/33
NCT04232241: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia

Recruiting
2
440
Europe, RoW
Allogeneic Stem Cell Transplantation
Universitätsklinikum Hamburg-Eppendorf, DKMS Stiftung Leben Spenden, Clinical Trial Center North (CTC North GmbH & Co. KG)
Acute Myeloid Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes
11/22
11/24
MYLOX-1, NCT04679870 / 2020-003087-45: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis

Active, not recruiting
2
21
Europe, US, RoW
GB2064
Galecto Biotech AB, OPIS s.r.l
Myelofibrosis
12/23
06/26
BlastCrisis, NCT03869502: European CML Blast Crisis Register

Recruiting
N/A
250
Europe, RoW
University of Jena
Chronic Myeloid Leukemia in Myeloid Blast Crisis
06/24
06/24
TAK-620-5010, NCT06615921: A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection

Recruiting
N/A
150
Europe, RoW
No Intervention
Takeda
Cytomegalovirus (CMV)
04/25
04/25
Thome, Ulrich H
FiO2-C, NCT03168516 / 2018-000453-41: Effects of Closed-loop Automatic Control of FiO2 in Extremely Preterm Infants

Active, not recruiting
3
1065
Europe, RoW
closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C)
University Hospital Tuebingen
Infant,Premature
12/26
12/26
Classen, Joseph
STRIDES, NCT05490563: - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia

Terminated
2/3
23
Europe, US, RoW
SLS-005, Placebo
Seelos Therapeutics, Inc.
Spinocerebellar Ataxia Type 3
11/23
11/23
PROSPER, NCT06355531: A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

Recruiting
2
220
Europe, US
FNP-223, Placebo
Ferrer Internacional S.A.
Progressive Supranuclear Palsy
11/26
11/26
Vancheri, C
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting
2
160
Europe, Canada, RoW
nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg
Trevi Therapeutics
Idiopathic Pulmonary Fibrosis
04/25
04/25
Moche, Michael
RESPECT, NCT05267080: Registry on Percutaneous Electrochemotherapy

Recruiting
N/A
250
Europe
CLINIPORATOR
Cardiovascular and Interventional Radiological Society of Europe
Primary Liver Cancer, Secondary Liver Cancer
01/26
01/27
Bernal, Vanesa
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
DHELIVER, NCT04229901: Study to Evaluate the Efficacy and Safety of HepaStem in Patients With Acute on Chronic Liver Failure (ACLF)

Terminated
2
133
Europe, RoW
HepaStem, Placebo
Cellaion SA
Acute on Chronic Liver Failure
05/24
05/24
Herling, Marco
CADENZA, NCT03386513 / 2018-003210-40: Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

Hourglass Jan 2024 - Dec 2024 : Top-line data from cohort 6 for 1L BPCDN
Active, not recruiting
1/2
179
Europe, US
IMGN632
AbbVie
Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
09/23
12/26
Petros, Sirak
ARISS, NCT03869385: Albumin Replacement Therapy in Septic Shock

Terminated
3
440
Europe
Albutein® 200 g/L or Plasbumin® 20, Human Albumin 20%
Jena University Hospital, German Research Foundation, Instituto Grifols, S.A., University Hospital Goettingen, SepNet - Critical Care Trials Group, Center for Sepsis Control and Care, Germany
Septic Shock
07/22
06/23
HerpMV, NCT06134492: Acyclovir in Mechanically Ventilated Patients With Pneumonia and HSV-1 in BAL

Recruiting
3
710
Europe
Acyclovir, Aciclovir
Jena University Hospital
Pneumonia, Viral, Ventilator Associated Pneumonia, Community-acquired Pneumonia, Herpes Simplex, Hospital-acquired Pneumonia
07/26
12/26
REMAP-CAP, NCT02735707 / 2015-002340-14: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
3
20000
Europe, Canada, Japan, US, RoW
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore
Community-acquired Pneumonia, Influenza, COVID-19
02/26
02/28
DigiSep, NCT04571801: Optimization of Sepsis Therapy Based on Patient-specific Digital Precision Diagnostics

Recruiting
N/A
410
Europe
Standard diagnostics, Next Generation Sequencing (NGS)
University Hospital, Essen, Noscendo GmbH, Germany, Health Economics and Health Care Management, Bielefeld University, Institute of Medical Biometry and Informatics, University of Heidelberg, Coordination Centre for Clinical Trials (KKS), University of Heidelberg, Department of Infectious Diseases, University Hospital Essen, Center for Infectious Diseases and Infection Control, Jena University Hospital, Department of Anesthesiology, Heidelberg University Hospital, AOK Health Insurance, Rheinland, Hamburg, Barmer Health Insurance, Germany, Techniker Health Insurance, Germany
Sepsis, Septic Shock
02/24
08/24
RODSS, NCT04610853: Rotational Thromboelastometry Versus DIC Score in Sepsis

Completed
N/A
100
Europe
rotational thromboelastometry
University of Leipzig
Sepsis, Septic Shock
03/24
05/24
IRATIC, NCT04599569: Influence of Renal Replacement TherApy on Indirect Calorimetry

Completed
N/A
100
Europe
indirect calorimetry
University of Leipzig
Acute Renal Failure, Mechanical Ventilation
05/24
06/24
PROCYSS, NCT04963920: A RCT to Assess the Performance of CytoSorb for Shock Reversal in Patients With Vasoplegic Septic Shock

Recruiting
N/A
260
Europe
Cytosorb® 300 ml
CytoSorbents Europe GmbH, BRAHMS GmbH, MedInnovation GmbH
Septic Shock
02/25
05/25
POS-VAP, NCT05719259: Perpetual Observational Study - Ventilator Associated Pneumonia

Recruiting
N/A
20000
Europe, RoW
VAP
European Clinical Research Alliance for Infectious Diseases (ECRAID), Centre Hospitalier Universitaire Dupuytren de Limoges (CHUL), Université de Genève (UNIGE), University Medical Center Utrecht (UMCU)
Ventilator Associated Pneumonia
12/25
03/26
Kunz, Kevin
RODSS, NCT04610853: Rotational Thromboelastometry Versus DIC Score in Sepsis

Completed
N/A
100
Europe
rotational thromboelastometry
University of Leipzig
Sepsis, Septic Shock
03/24
05/24
IRATIC, NCT04599569: Influence of Renal Replacement TherApy on Indirect Calorimetry

Completed
N/A
100
Europe
indirect calorimetry
University of Leipzig
Acute Renal Failure, Mechanical Ventilation
05/24
06/24
Seidel, Frank
RODSS, NCT04610853: Rotational Thromboelastometry Versus DIC Score in Sepsis

Completed
N/A
100
Europe
rotational thromboelastometry
University of Leipzig
Sepsis, Septic Shock
03/24
05/24
IRATIC, NCT04599569: Influence of Renal Replacement TherApy on Indirect Calorimetry

Completed
N/A
100
Europe
indirect calorimetry
University of Leipzig
Acute Renal Failure, Mechanical Ventilation
05/24
06/24
Meilick, Bianca
STRIDES, NCT05490563: - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia

Terminated
2/3
23
Europe, US, RoW
SLS-005, Placebo
Seelos Therapeutics, Inc.
Spinocerebellar Ataxia Type 3
11/23
11/23
Merz, Maximilian
AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Recruiting
3
482
Europe
Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD)
Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH
Multiple Myeloma
03/28
03/33
iinnovate-1, NCT03215030 / 2021-006038-37: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Completed
1/2
272
Europe, Canada, Japan, US, RoW
Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
07/24
11/24
Raab
MajesTEC-4, NCT05243797 / 2021-002531-27: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Recruiting
3
1594
Europe, Canada, US, RoW
Teclistamab, JNJ-64007957, Lenalidomide
Stichting European Myeloma Network, Janssen Pharmaceutica
Multiple Myeloma
04/28
04/32
CARTITUDE-6, NCT05257083 / 2021-003284-10: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Recruiting
3
750
Europe, Canada, Japan, US, RoW
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cilta-cel, JNJ-68284528, Cyclophosphamide, Fludarabine
Stichting European Myeloma Network, Janssen Research & Development, LLC
Multiple Myeloma
06/33
08/40
Merz
CARTITUDE-6, NCT05257083 / 2021-003284-10: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Recruiting
3
750
Europe, Canada, Japan, US, RoW
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cilta-cel, JNJ-68284528, Cyclophosphamide, Fludarabine
Stichting European Myeloma Network, Janssen Research & Development, LLC
Multiple Myeloma
06/33
08/40
Sandhya, M
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting
2
160
Europe, Canada, RoW
nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg
Trevi Therapeutics
Idiopathic Pulmonary Fibrosis
04/25
04/25
Overbeek, M
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting
2
160
Europe, Canada, RoW
nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg
Trevi Therapeutics
Idiopathic Pulmonary Fibrosis
04/25
04/25
Sanchez, J Roldan
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting
2
160
Europe, Canada, RoW
nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg
Trevi Therapeutics
Idiopathic Pulmonary Fibrosis
04/25
04/25
Martínez, JM Cifrian
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting
2
160
Europe, Canada, RoW
nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg
Trevi Therapeutics
Idiopathic Pulmonary Fibrosis
04/25
04/25
Villamor, M
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting
2
160
Europe, Canada, RoW
nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg
Trevi Therapeutics
Idiopathic Pulmonary Fibrosis
04/25
04/25
Hudig, L
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting
2
160
Europe, Canada, RoW
nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg
Trevi Therapeutics
Idiopathic Pulmonary Fibrosis
04/25
04/25
Wijsenbeek-Lourens, M
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting
2
160
Europe, Canada, RoW
nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg
Trevi Therapeutics
Idiopathic Pulmonary Fibrosis
04/25
04/25
Kramer, H
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting
2
160
Europe, Canada, RoW
nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg
Trevi Therapeutics
Idiopathic Pulmonary Fibrosis
04/25
04/25
Verdirosi, D
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting
2
160
Europe, Canada, RoW
nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg
Trevi Therapeutics
Idiopathic Pulmonary Fibrosis
04/25
04/25
Maznikoski, M
CORAL, NCT05964335: Cough Reduction in IPF with Nalbuphine ER

Recruiting
2
160
Europe, Canada, RoW
nalbuphine ER 27 mg, Active, Placebo, nalbuphine ER 54 mg, nalbuphine ER 108 mg
Trevi Therapeutics
Idiopathic Pulmonary Fibrosis
04/25
04/25

Download Options